Trovato Giovanni, Vezzani Antonio
European Commission, Joint Research Centre, Institute for Prospective Technological Studies (IPTS), Edificio Expo C/Inca Garcilaso, 3 E-41092 Seville, Spain.
Curr Drug Abuse Rev. 2013 Jun;6(2):144-51. doi: 10.2174/1874473706666131205152404.
This contribution provides an overview of different approaches used to analyse drug policies within and across countries. Besides the great number of cost of illness studies which have contributed to the assessment of health harms and risks associated to the drug use, most of the recent efforts have focused on the creation of synthetic indices to classify countries around the world or to evaluate particular law enforcement policies in some countries. This is probably due to a general lack of comparable data across countries. The wide variety of budgetary practices in the drugs field in Europe contributes to the problems that exist in estimating drug-related public expenditure. These heterogeneous accounting practices, together with the complexity of the drug phenomenon and the multiplicity of perspectives on the issue, strongly constrains the possibility of economically evaluate and compare drug laws across countries.
本论文概述了用于分析国内和跨国药物政策的不同方法。除了大量的疾病成本研究有助于评估与药物使用相关的健康危害和风险外,最近的大部分工作都集中在创建综合指数,以对世界各国进行分类,或评估某些国家的特定执法政策。这可能是由于各国普遍缺乏可比数据。欧洲药物领域广泛多样的预算做法加剧了估计与药物相关的公共支出时存在的问题。这些不同的会计做法,加上药物现象的复杂性和对该问题的多种观点,严重限制了对各国药物法律进行经济评估和比较的可能性。